MatriSys Bioscience

MatriSys announces positive results from a study of S. felis for the treatment of drug-resistant S. pseudintermedius. bit.ly/3aTYwlZ bit.ly/3DYNU1u #dermatology #skinmicrobiome

Dr. Philippe Calais, CEO of @MatriSysBio, will be presenting at the @MicrobiomeDaily 4th Microbiome Movement – Skin Health & Dermatology Summit (microbiome-dermatology.com) on August 4th at 4:15 p.m. ET. bit.ly/2VdKjLY

We are pleased to announce that Dr. Joyce Rico is joining MatriSys as Chief Medical Officer. Dr. Rico’s 20 years of experience in early and late-stage #dermatology drug development, product launch, and drug safety is a welcome addition to our team.

MatriSys Bioscience licenses compound for harnessing beneficial bacteria to treat #acne, building upon company pipeline targeting inflammatory skin diseases. bit.ly/3rZ2ro9 #dermatology #skinmicrobiome

MatriSys Bioscience raises more than $3 million to advance its platform developing #skinmicrobiome therapies for inflammatory skin diseases. #dermatology

Published @NatureMedicine study on @MatriSysBio’s lead compound for #atopicdermatitis reveals the potential of beneficial bacteria to treat chronic skin diseases. bit.ly/3qOt92g #dermatology #microbiome

Important new science from the NIH - How genetic variations cause eczema nih.gov/news-events/ne…

MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by Connect/San Diego Venture Group (SDVG). bit.ly/2XakFpR

MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors bit.ly/2XzHlyX

MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors bit.ly/3bQucXv

This is an important concept. Colonization is not the same thing as infection. Bleach baths and antibiotics aren't very effective against colonized bacteria. Acne is a good model to explain this. lnkd.in/gDVVFDB

MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis. The positive feedback received from the FDA is encouraging and paves the way for Phase 2. bit.ly/2YcmLnR

MatriSys Bioscience Inc. has appointed longtime life science executive Jennifer Giottonini Cayer to its Board of Directors. Ms. Cayer brings more than 25 years of leadership experience spanning biotech, pharmaceutical and medical devices. bit.ly/2XYphxU

MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has submitted a pre-IND (Investigational New Drug) meeting request letter to the U.S. FDA for planned Phase 2 bit.ly/2R6iwKz

Tonight!! San Diego Central Library CITIZEN SCIENCE: MatriSys Bioscience sandiego.librarymarket.com/citizen-scienc…

Thursday night at the San Diego Public Library!! meetup.com/The-Wet-Lab/ev…

BioCentury!! biocentury.com/biocentury/eme…

Buzz of Bio!! Vote for us!! How to vote for us: Go here: convention.bio.org/buzzofbio/voti… Complete each field on the right side of the page Be sure to select MatriSys Bioscience under Pipelines of Promise Hit submit Follow the link in the confirmation email to verify your vote